CITY THERAPEUTICS, INC.

City Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapeutics to silence disease-relevant proteins. The company aims to deliver meaningful and durable benefits for patients with unmet medical needs, including thromboembolic diseases, Stargardt disease type 1, and anemia of chronic disease. City Therapeutics leverages its RNAi expertise and City Platform capabilities to develop potentially best-in-class therapeutics.